
China Pharma Holdings Market Cap | CPHI
As of November 19, 2026 China Pharma Holdings has a market cap of $ 2.19 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.75 M | 454 K | 1.25 M | 368 K | 2.21 M | 30.9 M | 18.3 M | 12.6 M | 14.8 M | 10.9 M | 6.1 M | 13.1 M | 18.7 M | 10.9 M | 33 M | 59.2 B | 30 B |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.2 B | 368 K | 5.26 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Lannett Company
LCI
|
23 M | - | 1.15 % | $ 7.11 M | ||
|
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | ||
|
Evoke Pharma
EVOK
|
187 K | - | - | $ 36.6 M | ||
|
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | ||
|
Radius Health
RDUS
|
393 M | - | - | $ 1.42 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B | ||
|
PetIQ
PETQ
|
396 B | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
623 M | $ 6.35 | 1.85 % | $ 556 M | ||
|
TherapeuticsMD
TXMD
|
23 M | $ 1.82 | -4.71 % | $ 21.1 M | ||
|
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | ||
|
cbdMD
YCBD
|
3.58 M | $ 0.37 | 1.62 % | $ 1.49 M | ||
|
Aurora Cannabis
ACB
|
224 M | $ 4.41 | -2.43 % | $ 242 M | ||
|
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | ||
|
Tricida
TCDA
|
408 M | - | - | $ 3.25 M | ||
|
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | ||
|
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | ||
|
PLx Pharma
PLXP
|
119 M | - | -27.8 % | $ 2.56 M | ||
|
Tilray
TLRY
|
614 M | $ 2.25 | -4.06 % | $ 252 M | ||
|
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | ||
|
Relmada Therapeutics
RLMD
|
247 M | $ 2.86 | -4.98 % | $ 113 M | ||
|
OptiNose
OPTN
|
12.8 M | - | - | $ 1.08 B | ||
|
Canopy Growth Corporation
CGC
|
292 M | $ 0.5 | -5.01 % | $ 149 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
84.8 M | $ 6.38 | 10.0 % | $ 94.8 M | ||
|
Harrow Health
HROW
|
1.93 B | $ 32.2 | 9.08 % | $ 1.18 B | ||
|
Pacira BioSciences
PCRX
|
1.17 B | $ 36.48 | 0.05 % | $ 1.63 B | ||
|
Emergent BioSolutions
EBS
|
452 M | $ 5.5 | -1.96 % | $ 294 M | ||
|
Cronos Group
CRON
|
736 M | $ 3.17 | -0.63 % | $ 1.22 B | ||
|
Evolus
EOLS
|
271 M | $ 7.07 | 5.61 % | $ 456 M | ||
|
Organogenesis Holdings
ORGO
|
337 M | $ 0.85 | 4.57 % | $ 108 M | ||
|
Rockwell Medical
RMTI
|
33.8 M | $ 6.32 | -4.38 % | $ 227 M | ||
|
Bausch Health Companies
BHC
|
2.03 B | $ 8.74 | 3.13 % | $ 3.24 B | ||
|
OrganiGram Holdings
OGI
|
151 M | $ 0.68 | -4.46 % | $ 64.8 M | ||
|
Perrigo Company plc
PRGO
|
1.96 B | $ 16.98 | 7.71 % | $ 2.35 B | ||
|
SCYNEXIS
SCYX
|
37.9 M | $ 2.81 | -1.4 % | $ 140 M | ||
|
Veru
VERU
|
84.9 M | $ 2.3 | 7.48 % | $ 33.7 M | ||
|
HEXO Corp.
HEXO
|
276 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1 B | - | -0.1 % | $ 2.03 B | ||
|
Viatris
VTRS
|
18.4 B | $ 20.27 | -0.86 % | $ 23.2 B | ||
|
Sundial Growers
SNDL
|
348 M | $ 1.35 | 0.37 % | $ 348 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
1.85 M | $ 0.82 | -1.81 % | $ 1.38 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
75.4 M | - | - | $ 150 M | ||
|
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | ||
|
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M |